Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.27 USD
Change Today -0.0015 / -0.56%
Volume 375.3K
ETRM On Other Exchanges
As of 8:10 PM 10/9/15 All times are local (Market data is delayed by at least 15 minutes).

enteromedics inc (ETRM) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/14/15 - $2.05
52 Week Low
08/24/15 - $0.20
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ENTEROMEDICS INC (ETRM)

enteromedics inc (ETRM) Related Businessweek News

No Related Businessweek News Found

enteromedics inc (ETRM) Details

EnteroMedics Inc., a medical device company, focuses on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company’s proprietary neuroblocking technology is designed to intermittently block the vagus nerve using electrical impulses. It develops the Maestro Rechargeable System, which is used to limit the expansion of the stomach, control hunger sensations between meals, reduce the frequency and intensity of stomach contractions, and produce a feeling of early and prolonged fullness. The company is evaluating the Maestro System in human clinical trials in the United States, Australia, and Mexico. It has collaboration with Mayo Clinic for the development and testing of products for the treatment of obesity. The company was formerly known as Beta Medical, Inc. and changed its name to EnteroMedics Inc. in 2003. EnteroMedics Inc. was founded in 2002 and is headquartered in St. Paul, Minnesota.

28 Employees
Last Reported Date: 03/13/15
Founded in 2002

enteromedics inc (ETRM) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $410.2K
Co-Founder and Vice President of Clinical & R...
Total Annual Compensation: $297.2K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $338.3K
Senior Vice President of Research and Advance...
Total Annual Compensation: $296.6K
Compensation as of Fiscal Year 2014.

enteromedics inc (ETRM) Key Developments

EnteroMedics Receives Non-Compliance Notice From NASDAQ

On September 10, 2015, EnteroMedics Inc. received a written notice from the Listing Qualifications department of The Nasdaq Stock Market (Nasdaq) notifying the Company that, for the last 30 consecutive business days, the Company has failed to comply with Nasdaq Listing Rule 5550(b)(2), which requires the Company to maintain a minimum “Market Value of Listed Securities” of $35 million for continued listing on the Nasdaq Capital Market. The Notice also stated that the Company did not meet the alternative requirements under Listing Rules 5550(b)(1) or 5550(b)(3). In accordance with Listing Rule 5810(c)(3)(C), NASDAQ has granted the Company a period of 180 calendar days, or until March 8, 2016, to regain compliance with Listing Rule 5550(b)(2). The Company may regain compliance with the Listing Rule at any time during this compliance period if its Market Value of Listed Securities closes at $35 million or more for a minimum of ten consecutive business days. In the event the Company does not regain compliance with Listing Rule 5550(b)(2) or the other compliance alternatives under Listing Rule 5550(b) prior to the expiration of the compliance period, it will receive written notification that its securities are subject to delisting, at which time the Company may appeal the delisting determination to a Hearings Panel. The Company intends to actively monitor its Market Value of Listed Securities between now and March 8, 2016, and will consider available options to resolve the deficiency and regain compliance with Listing Rule 5550(b)(2).

EnteroMedics Inc., Board Meeting, Aug 20, 2015

EnteroMedics Inc., Board Meeting, Aug 20, 2015. Agenda: To consider the retirement of Mark B. Knudson as Chief Executive Officer ( CEO ) and President as of December 31, 2015.

EnteroMedics Inc. Announces Management Changes

EnteroMedics Inc. announced that Mark B. Knudson, Ph.D., EnteroMedics Founder, Chairman, President and Chief Executive Officer notified the company of his intention to retire effective December 31, 2015. Dr. Knudson will remain Chairman of the EnteroMedics Board of Directors. The company also announced that Jon Tremmel, a member of the company's board of directors, has been appointed as Consultant to the CEO. Mr. Tremmel will lead a search committee to find a successor for the chief executive role as well as provide strategic advice to the company regarding its commercialization and reimbursement activities during the transition.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ETRM:US $0.27 USD -0.0015

ETRM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ETRM.
View Industry Companies

Industry Analysis


Industry Average

Valuation ETRM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 251.3x
Price/Book 13.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 286.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENTEROMEDICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at